Viatris Inc (VTRS) Actualités

Viatris to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Viatris to Present at the 43rd Annual J.P. Morgan Healthcare Conference PR Newswire PITTSBURGH, Jan. 7, 2025...

Form 4 - Statement of changes in beneficial ownership of securities

Viatris Announces Publication of Phase 2b CARE Study Data for Cenerimod in Lancet Rheumatology

Viatris Announces Publication of Phase 2b CARE Study Data for Cenerimod in Lancet Rheumatology PR...

Form 8-K - Current report

Form 8-K - Current report

Viatris Reports Third Quarter Financial Results for 2024

Viatris Reports Third Quarter Financial Results for 2024 PR Newswire PITTSBURGH, Nov. 7, 2024 PITTSBURGH, Nov...

Viatris Announces Third Quarter 2024 Dividend

Viatris Announces Third Quarter 2024 Dividend PR Newswire PITTSBURGH, Nov. 5, 2024 PITTSBURGH, Nov. 5, 2024...

Viatris Named to Forbes' World's Top Companies for Women 2024 List

Viatris Named to Forbes' World's Top Companies for Women 2024 List PR Newswire PITTSBURGH, Oct. 29, 2024...

Viatris to Participate in the UBS Global Healthcare Conference and Jefferies London Healthcare Conference

Viatris to Participate in the UBS Global Healthcare Conference and Jefferies London Healthcare Conference PR...

Form ARS - Annual Report to Security Holders

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Form DEF 14A - Other definitive proxy statements

Lexicon Announces Exclusive Licensing Agreement With Viatris for Sotagliflozin in All Markets Outside of the U.S. and Europe

THE WOODLANDS, Texas, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today...

Viatris Announces Exclusive Licensing Agreement with Lexicon Pharmaceuticals for Sotagliflozin in all Markets Outside of the U.S. and Europe

Viatris Announces Exclusive Licensing Agreement with Lexicon Pharmaceuticals for Sotagliflozin in all Markets...

Viatris Announces Positive Top-line Results from Phase 3 Study of EFFEXOR® in Japanese Adults with Generalized Anxiety Disorder (GAD)

Viatris Announces Positive Top-line Results from Phase 3 Study of EFFEXOR® in Japanese Adults with Generalized...